source
- Sanofi halts Phase 3 trial of riliprubart in CIDP after interim analysis shows unlikely efficacySanofi announced Wednesday that it is stopping the Phase 3 MOBILIZE study of its experimental anti‑inflammatory drug riliprubart in patients with chronic inflammatory demyelinating polyneuropathy (…
- Ethyreal Bio raises $101M to develop antibody targeting Graves disease and thyroid eye diseaseEthyreal Bio, a Cambridge-based biotech that has just emerged from stealth mode, announced it has closed a $101 million financing round to advance its lead candidate. The company’s candidate, a mo…